Eli Lilly (LLY) Long-Term Investments (2009 - 2026)

Eli Lilly (LLY) has reported Long-Term Investments for 18 consecutive years, with $3.1 billion the latest figure, recorded in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $3.1 billion, down 3.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 billion (down 3.31% YoY), and the FY2025 annual result was $2.8 billion, down 12.87% from the prior year.
• Long-Term Investments was $3.1 billion for Q1 2026 at Eli Lilly, up from $2.8 billion in the prior quarter.
• Over five years, Long-Term Investments peaked at $3.2 billion in Q1 2025 and troughed at $2.6 billion in Q3 2022.
• Average Long-Term Investments over 5 years is $2.9 billion, with a median of $2.9 billion recorded in 2024.
• Year-over-year, Long-Term Investments fell 25.55% in 2022 and grew 18.89% in 2024.
• Over 5 years, Long-Term Investments stood at $2.9 billion in 2022, then increased by 5.18% to $3.1 billion in 2023, then increased by 5.37% to $3.2 billion in 2024, then decreased by 12.87% to $2.8 billion in 2025, then advanced by 11.21% to $3.1 billion in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $3.1 billion in Q1 2026, $2.8 billion in Q4 2025, and $2.8 billion in Q3 2025.